PMID- 25270122
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20181202
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 148
IP  - 1
DP  - 2014 Nov
TI  - Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved 
      progression-free survival in patients with human epidermal growth factor receptor 
      (HER2)-positive advanced breast cancer.
PG  - 197-209
LID - 10.1007/s10549-014-3148-7 [doi]
AB  - This study is aimed to identify clinical predictors, other than HER2 
      overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in 
      patients with HER2-positive advanced breast cancer (HER2ABC). Data from our 
      medical records of 76 patients from June 2009 to March 2013 were analyzed. 
      Evaluations of these patients with HER2ABC treated with LAPCAP included baseline 
      characteristics, dose modifications, efficacy, and incidence of adverse events 
      (AEs). With a median follow-up of 20 months, the median number of prior therapies 
      for ABC before LAPCAP was 2 (range 0-13), and 66 patients had previously received 
      trastuzumab. For LAPCAP, the overall response rate was 21 %, and the clinical 
      benefit rate was 60 %. During the initial 12-month observation period, 93 % of 
      patients had AEs. The most common AE was hand-foot syndrome (HFS) in 55 patients. 
      Progression-free survival (PFS) was better in patients who had HFS than in those 
      who did not (p = 0.0002). Since HFS is a well-known AE associated with CAP, 
      whether CAP dose affected PFS or not was investigated, but no positive 
      relationship was found. Since several studies with EGFR-targeted agents have 
      suggested a positive correlation between cutaneous toxicities and outcomes, 
      whether the incidence of any AEs affected PFS or not was explored among 76 
      patients. HFS, diarrhea, and rash were significant favorable factors (p = 0.0002, 
      0.0088, and 0.0011). The median PFS of patients who had all three AEs was 
      13.2 months, compared with 2.6 months for those who did not (p = 0.00000174). 
      Mucocutaneous toxicities may be predictors of the response to LAP in patients 
      with HER2ABC.
FAU - Araki, Kazuhiro
AU  - Araki K
AD  - Beast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of 
      the Japanese Foundation for Cancer Research, 3-8-31 Ariake Koto-ku, Tokyo, 
      135-8550, Japan, kazuhiro.araki@jfcr.or.jp.
FAU - Fukada, Ippei
AU  - Fukada I
FAU - Horii, Rie
AU  - Horii R
FAU - Takahashi, Shunji
AU  - Takahashi S
FAU - Akiyama, Futoshi
AU  - Akiyama F
FAU - Iwase, Takuji
AU  - Iwase T
FAU - Ito, Yoshinori
AU  - Ito Y
LA  - eng
PT  - Journal Article
DEP - 20141001
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (Lapatinib)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Breast Neoplasms/*drug therapy/mortality
MH  - Capecitabine
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Diarrhea/*chemically induced
MH  - Disease-Free Survival
MH  - *Drug Eruptions
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lapatinib
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Quinazolines/administration & dosage/*adverse effects
MH  - Receptor, ErbB-2
MH  - Retrospective Studies
EDAT- 2014/10/02 06:00
MHDA- 2015/06/17 06:00
CRDT- 2014/10/02 06:00
PHST- 2014/03/26 00:00 [received]
PHST- 2014/09/20 00:00 [accepted]
PHST- 2014/10/02 06:00 [entrez]
PHST- 2014/10/02 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
AID - 10.1007/s10549-014-3148-7 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2014 Nov;148(1):197-209. doi: 10.1007/s10549-014-3148-7. 
      Epub 2014 Oct 1.